Cello Group plc (LON:CLL)‘s stock had its “buy” rating restated by equities researchers at N+1 Singer in a note issued to investors on Tuesday. They currently have a GBX 128 ($1.67) price target on the stock, up from their previous price target of GBX 127 ($1.66). N+1 Singer’s target price suggests a potential upside of 19.63% from the company’s previous close.

Other equities analysts have also issued reports about the company. Cenkos Securities Ltd reaffirmed a “buy” rating on shares of Cello Group plc in a research note on Wednesday, September 14th. Peel Hunt reaffirmed a “buy” rating and set a GBX 130 ($1.70) price target on shares of Cello Group plc in a research note on Tuesday, July 26th.

Shares of Cello Group plc (LON:CLL) opened at 106.00 on Tuesday. Cello Group plc has a 12 month low of GBX 77.10 and a 12 month high of GBX 115.00. The stock has a 50 day moving average price of GBX 104.04 and a 200-day moving average price of GBX 97.59. The stock’s market cap is GBX 92.16 million.

The business also recently disclosed a dividend, which will be paid on Friday, November 4th. Stockholders of record on Thursday, October 6th will be given a dividend of GBX 1 ($0.01) per share. The ex-dividend date of this dividend is Thursday, October 6th. This represents a dividend yield of 0.94%.

Cello Group plc Company Profile

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with Analyst Ratings Network's FREE daily email newsletter.